🇺🇸 FDA
Pipeline program

MKC-1

MKC-104

Phase 1 small_molecule completed

Quick answer

MKC-1 for Hematological Malignancies is a Phase 1 program (small_molecule) at CASI Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
CASI Pharmaceuticals
Indication
Hematological Malignancies
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials